YUCAIPA, Calif., July 15, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has rescheduled the annual shareholder meeting for September 22, 2009.
"There has been a significant change in the number of shareholders for this company in the past few weeks. It would have been unfair to conduct our scheduled annual meeting without notification to the new shareholders. Therefore, we will be sending new notices and proxy statements to all of our shareholders in the next few weeks. This is a good opportunity for the shareholders to learn more about our progress and vote on important matters concerning our growth," stated Thomas J. Neavitt, Chief Financial Officer of Ingen Technologies.
The company will hold the annual shareholder meeting on Tuesday, September 22, 2009 starting at 10:00am located at 35193 Avenue A, Yucaipa, California. The proxy statement and consent will include instructions to the shareholder to send their vote in by fax or mail. All shareholders of record will receive the proxy statement, most current year-end statement and meeting agenda.
"The company has extinguished all of the accumulated operational debt, as well as has an increase in product sales. Moving forward, our focus is on product sales and distribution. These items will be forecast at the annual shareholder meeting. I look forward to a bright and successful future for this company," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
About Ingen Technologies/Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
www.ingen-tech.com
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment